Business News • PR NewsWire • Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278

Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278

Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278

CORK, Ireland, September 3, 2010 /PRNewswire/ -- Tibotec Pharmaceuticals today announced its submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TMC278 (rilpivirine, as hydrochloride), an investigational non-nucleoside reverse transcriptase inhibi

View More : http://www.prnewswire.com/news-releases/tibotec-pharmaceuticals-seeks-european-marketing-authorization-for-investigation...

Releted News by prnewswire